Compare Stocks: CVKD, BFRI, FNCH, and INTS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BFRI Biofrontera	$0.87 -6.3%	$1.15	$0.55 ▼ $1.66	$13.84M	0.86	232,612 shs	281,821 shs
CVKD Cadrenal Therapeutics	$0.99 +4.4%	$1.14	$0.82 ▼ $13.75	$3.37M	1.93	204,747 shs	80,671 shs
FNCH Finch Therapeutics Group	$7.30	$7.30	$2.00 ▼ $16.10	$11.72M	1.18	5,025 shs	N/A
INTS Intensity Therapeutics	$3.40 +1.8%	$3.77	$3.00 ▼ $28.75	$10.90M	2.81	20,242 shs	16,111 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BFRI Biofrontera	+5.09%	+19.27%	-14.54%	-20.38%	-12.12%
CVKD Cadrenal Therapeutics	-0.47%	-2.74%	-13.45%	-53.06%	-92.66%
FNCH Finch Therapeutics Group	0.00%	0.00%	0.00%	0.00%	-46.48%
INTS Intensity Therapeutics	-1.18%	+4.15%	-2.34%	-19.52%	-49.96%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BFRI Biofrontera	$0.87 -6.3%	$1.15	$0.55 ▼ $1.66	$13.84M	0.86	232,612 shs	281,821 shs
CVKD Cadrenal Therapeutics	$0.99 +4.4%	$1.14	$0.82 ▼ $13.75	$3.37M	1.93	204,747 shs	80,671 shs
FNCH Finch Therapeutics Group	$7.30	$7.30	$2.00 ▼ $16.10	$11.72M	1.18	5,025 shs	N/A
INTS Intensity Therapeutics	$3.40 +1.8%	$3.77	$3.00 ▼ $28.75	$10.90M	2.81	20,242 shs	16,111 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BFRI Biofrontera	+5.09%	+19.27%	-14.54%	-20.38%	-12.12%
CVKD Cadrenal Therapeutics	-0.47%	-2.74%	-13.45%	-53.06%	-92.66%
FNCH Finch Therapeutics Group	0.00%	0.00%	0.00%	0.00%	-46.48%
INTS Intensity Therapeutics	-1.18%	+4.15%	-2.34%	-19.52%	-49.96%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BFRI Biofrontera	2.00	Hold	N/A	N/A
CVKD Cadrenal Therapeutics	2.00	Hold	$13.00	1,219.80% Upside
FNCH Finch Therapeutics Group	0.00	N/A	N/A	N/A
INTS Intensity Therapeutics	2.80	Moderate Buy	$7.00	105.88% Upside

Current Analyst Ratings Breakdown

Latest CVKD, BFRI, FNCH, and INTS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/19/2026	INTS Intensity Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
10/15/2026	CVKD Cadrenal Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
10/13/2026	BFRI Biofrontera	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
8/18/2026	INTS Intensity Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$5.00 ➝ $7.00
8/11/2026	INTS Intensity Therapeutics	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
8/3/2026	BFRI Biofrontera	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong Sell ➝ Hold

(Data available from 10/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BFRI Biofrontera	$41.71M	0.31	N/A	N/A	$0.90 per share	0.97
CVKD Cadrenal Therapeutics	N/A	N/A	N/A	N/A	$1.17 per share	N/A
FNCH Finch Therapeutics Group	N/A	N/A	N/A	N/A	$14.25 per share	N/A
INTS Intensity Therapeutics	N/A	N/A	N/A	N/A	$4.94 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BFRI Biofrontera	-$10.54M	-$0.45	N/A	N/A	N/A	-13.78%	-145.81%	-31.30%	11/11/2026 (Estimated)
CVKD Cadrenal Therapeutics	-$13.24M	-$4.90	N/A	N/A	N/A	N/A	-406.41%	-273.80%	11/9/2026 (Estimated)
FNCH Finch Therapeutics Group	-$74.75M	-$8.82	N/A	N/A	N/A	N/A	-69.14%	-26.92%	N/A
INTS Intensity Therapeutics	-$11.61M	-$3.57	N/A	N/A	N/A	N/A	-116.61%	-94.01%	11/5/2026 (Estimated)

Latest CVKD, BFRI, FNCH, and INTS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/11/2026	Q3 2026	BFRI Biofrontera	-$0.22	N/A	N/A	N/A	$8.25 million	N/A
11/9/2026	Q3 2026	CVKD Cadrenal Therapeutics	-$0.91	N/A	N/A	N/A	N/A	N/A
11/5/2026	Q3 2026	INTS Intensity Therapeutics	-$0.94	N/A	N/A	N/A	N/A	N/A
8/13/2026	Q2 2026	BFRI Biofrontera	-$0.1050	-$0.05	+$0.0550	-$0.05	$9.50 million	$12.00 million
8/13/2026	Q2 2026	CVKD Cadrenal Therapeutics	-$1.42	-$1.14	+$0.28	-$1.14	N/A	N/A
8/11/2026	Q2 2026	INTS Intensity Therapeutics	-$0.8725	-$1.11	-$0.2375	-$1.11	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BFRI Biofrontera	N/A	N/A	N/A	N/A	N/A
CVKD Cadrenal Therapeutics	N/A	N/A	N/A	N/A	N/A
FNCH Finch Therapeutics Group	N/A	N/A	N/A	N/A	N/A
INTS Intensity Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BFRI Biofrontera	0.78	1.18	1.08
CVKD Cadrenal Therapeutics	N/A	3.73	3.73
FNCH Finch Therapeutics Group	N/A	3.87	3.87
INTS Intensity Therapeutics	0.01	5.00	5.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BFRI Biofrontera	10.08%
CVKD Cadrenal Therapeutics	7.92%
FNCH Finch Therapeutics Group	21.77%
INTS Intensity Therapeutics	3.74%

Insider Ownership

Company	Insider Ownership
BFRI Biofrontera	8.10%
CVKD Cadrenal Therapeutics	14.59%
FNCH Finch Therapeutics Group	44.90%
INTS Intensity Therapeutics	7.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BFRI Biofrontera	94	14.85 million	13.65 million	No Data
CVKD Cadrenal Therapeutics	5	3.57 million	3.05 million	Not Optionable
FNCH Finch Therapeutics Group	190	1.61 million	885,000	No Data
INTS Intensity Therapeutics	2,021	3.26 million	3.02 million	Not Optionable

CVKD, BFRI, FNCH, and INTS Headlines

Recent News About These Companies

Intensity Therapeutics to Announce Third Quarter 2026 Financial Results on November 5, 2026

October 30 at 8:00 AM | prnewswire.com

Intensity Therapeutics Inc. (NASDAQ:INTS) Stock Rated "Moderate Buy" by Wall Street Brokerages

October 30 at 2:58 AM | americanbankingnews.com

Intensity Therapeutics, Inc. to Present INVINCIBLE-4 Neoadjuvant Triple-Negative Breast Cancer Study Data for the First Seven (7) Patients After INT230-6 Treatment (Cohort A) in an ePoster Presentation at the European Society of Medical Oncology (ESMO) Meeting

October 23, 2026 | prnewswire.com

Intensity Therapeutics (NASDAQ:INTS) Stock Price Up 2.1% - What's Next?

October 23, 2026 | americanbankingnews.com

Intensity Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

September 8, 2026 | prnewswire.com

Intensity's Q2 Loss Widens Marginally As Trials For Breast Cancer Drug Resume

September 4, 2026 | rttnews.com

Intensity Therapeutics (INTS) Q2 2026 Earnings Call Transcript

August 12, 2026 | finance.yahoo.com

Intensity therapeutics targets INVINCIBLE-4 enrollment completion by end of 2027 while seeking $30M to finish INVINCIBLE-3

August 11, 2026 | seekingalpha.com

Intensity Therapeutics, Inc. (INTS) Q2 2026 Earnings Call Transcript

August 11, 2026 | seekingalpha.com

Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

August 11, 2026 | prnewswire.com

Intensity Therapeutics to Announce Second Quarter 2026 Financial Results on August 11, 2026

August 4, 2026 | prnewswire.com

Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study)

July 15, 2026 | prnewswire.com

Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6

July 1, 2026 | prnewswire.com

Intensity Therapeutics Inc. (INTS) Upgraded to Buy: Here's Why

May 27, 2026 | zacks.com

Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award

May 14, 2026 | prnewswire.com

Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 7, 2026 | prnewswire.com

Intensity Therapeutics Inc. (INTS) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

May 1, 2026 | zacks.com

Intensity Therapeutics (INTS) price target decreased by 12.76% to 49.98

April 28, 2026 | msn.com

Intensity Therapeutics Inc. (INTS) Upgraded to Buy: Here's What You Should Know

April 16, 2026 | zacks.com

Intensity Therapeutics Recognized with Pinnacle Award for Excellence in Healthcare Innovation

April 15, 2026 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVKD, BFRI, FNCH, and INTS Company Descriptions

Biofrontera NASDAQ:BFRI

$0.87 -0.06 (-6.29%)

Closing price 04:00 PM Eastern

Extended Trading

$0.89 +0.01 (+1.50%)

As of 07:37 PM Eastern

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Cadrenal Therapeutics NASDAQ:CVKD

$0.98 +0.04 (+4.41%)

Closing price 04:00 PM Eastern

Extended Trading

$1.00 +0.02 (+1.52%)

As of 07:30 PM Eastern

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Finch Therapeutics Group NASDAQ:FNCH

$7.30 0.00 (0.00%)

As of 10/29/2026

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.

Intensity Therapeutics NASDAQ:INTS

$3.40 +0.06 (+1.80%)

Closing price 04:00 PM Eastern

Extended Trading

$3.40 +0.00 (+0.15%)

As of 07:41 PM Eastern

Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CVKD, BFRI, FNCH, and INTS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CVKD, BFRI, FNCH, and INTS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CVKD, BFRI, FNCH, and INTS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVKD, BFRI, FNCH, and INTS Company Descriptions

Biofrontera NASDAQ:BFRI

Cadrenal Therapeutics NASDAQ:CVKD

Finch Therapeutics Group NASDAQ:FNCH

Intensity Therapeutics NASDAQ:INTS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CVKD, BFRI, FNCH, and INTS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CVKD, BFRI, FNCH, and INTS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CVKD, BFRI, FNCH, and INTS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVKD, BFRI, FNCH, and INTS Company Descriptions

Biofrontera NASDAQ:BFRI

Cadrenal Therapeutics NASDAQ:CVKD

Finch Therapeutics Group NASDAQ:FNCH

Intensity Therapeutics NASDAQ:INTS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools